Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

PD-L1 anticorps

Cet anticorps anti-PD-L1 est un anticorps Lapin Monoclonal détectant PD-L1 dans IHC et ELISA. Adapté pour Humain.
N° du produit ABIN7566411

Aperçu rapide pour PD-L1 anticorps (ABIN7566411)

Antigène

Voir toutes PD-L1 Anticorps
PD-L1 (CD274 (PD-L1))

Reactivité

  • 225
  • 146
  • 65
  • 6
  • 6
  • 5
  • 5
  • 1
  • 1
Humain

Hôte

  • 135
  • 106
  • 27
  • 5
  • 4
  • 4
  • 2
  • 1
Lapin

Clonalité

  • 159
  • 116
  • 7
Monoclonal

Conjugué

  • 117
  • 23
  • 17
  • 17
  • 13
  • 5
  • 5
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Cet anticorp PD-L1 est non-conjugé

Application

  • 167
  • 152
  • 65
  • 63
  • 40
  • 33
  • 28
  • 22
  • 22
  • 14
  • 11
  • 9
  • 7
  • 7
  • 6
  • 3
  • 3
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Immunohistochemistry (IHC), ELISA

Clone

AG-IHC411
  • Fonction

    anti-PD-L1 (human), mAb (AG-IHC411)

    Attributs du produit

    Monoclonal Antibody. Recognizes human PD-L1 (CD274). Applications: ELISA, IHC. Isotype: Rabbit IgG. Clone: AG-IHC411. Liquid. In Tris Buffer, pH 7.4, containing 1 % BSA and <0.1 % sodium azide. Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. PD-L1 is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8+ T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. PD-L1 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8+ tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer and sentinel lymph node melanoma. This antibody is intended to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods. It has been optimized and validated using the BOND-MAX fully automated IHC&ISH stainer (see Protocol).

    Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. PD-L1 is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8+ T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. PD-L1 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8+ tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer and sentinel lymph node melanoma. This antibody is intended to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods. It has been optimized and validated using the BOND-MAX fully automated IHC&ISH stainer (see Protocol).

    Purification

    Protein A/G purified.

    Immunogène

    Recombinant human PD-L1.

    Isotype

    IgG
  • Indications d'application

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Buffer

    In Tris Buffer, pH 7.4, containing 1 % BSA and <0.1 % sodium azide.

    Agent conservateur

    Sodium azide

    Précaution d'utilisation

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Conseil sur la manipulation

    Do not freeze.

    Stock

    4 °C

    Stockage commentaire

    Stable for at least 1 year after receipt when stored at +4°C.

  • Antigène

    PD-L1 (CD274 (PD-L1))

    Autre désignation

    PD-L1

    UniProt

    Q9NZQ7

    Pathways

    Cancer Immune Checkpoints
Vous êtes ici:
Chat with us!